EXHIBIT 24.3
Published on October 3, 1996
EXHIBIT 24.3
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to inclusion in this Registration Statement on Form
SB-2 of our report dated February 2, 1996 on our audits of the financial
statements of Cytoclonal Pharmaceutics Inc. We also consent to the reference of
our firm under the captions "Experts" and "Selected Financial Data" in the
Prospectus.
Richard A. Eisner & Company, LLP
New York, New York
September 30, 1996
BRYAN CAVE LLP
245 Park Avenue
New York, N.Y. 10167
ROBERT H. COHEN (212) 692-1843
October 2, 1996
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Division of Corporate Finance
Re: Cytoclonal Pharmaceutics Inc.
Form SB-2
-----------------------------
Ladies and Gentlemen:
Enclosed herewith for filing on behalf of Cytoclonal Pharmaceutics Inc.
(the "Company") pursuant to the Securities Act of 1933, as amended, is a
complete copy of the Company's Registration Statement on Form SB-2, including
all exhibits. Originally executed and dated signature pages and consent of
independent accountants have been maintained by the Company.
We are desirous of circulating a prospectus to shareholders as
soon as possible; therefore, we would appreciate the Staff's comments, if any,
communicated to our attention as early as possible.
Very truly yours,
BRYAN CAVE LLP
By:___________________________
Robert H. Cohen
RHC:DY
Enclosure
cc: Daniel M. Shusterman, Esq.